By Fineline Cube 
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US in a global multicenter Phase III clinical trial evaluating HLX22 combined with trastuzumab and XELOX chemotherapy. The trial compares this combination against trastuzumab/XELOX with or without pembrolizumab as first-line treatment for HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (GC/GEJC).
HLX22: Innovative HER2-Targeted Therapy
HLX22 is an innovative HER2-targeted monoclonal antibody licensed from AbClon, Inc. It is under development for the treatment of solid tumors, including gastric and breast cancers. The drug has been granted Orphan Drug Designations by the U.S. FDA and European Commission for gastric cancer in March and May this year, respectively.
Global Clinical Development
This Phase III trial marks a significant step in the global development of HLX22, highlighting Henlius Biotech’s commitment to advancing therapeutic options for patients with HER2-positive GC/GEJC. The trial aims to evaluate the efficacy and safety of HLX22 in combination with standard therapies.-Fineline Info & Tech